Mirae Asset Global Investments
HRTX icon

Mirae Asset Global Investments’s Heron Therapeutics HRTX Stock Holding History

Mirae Asset Global Investments’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-32,615
Closed -$52.5K – 1995
2024
Q1 		$52.5K Buy
+32,615
New +$82K ﹤0.01% 2423
2023
Q2 		– Sell
-32,615
Closed -$49.2K – 2645
2023
Q1 		$49.2K Buy
32,615
+10,791
+49% +$27K ﹤0.01% 2510
2022
Q4 		$54.6K Hold
21,824
– – ﹤0.01% 2517
2022
Q3 		$92K Sell
21,824
-5,421
-20% -$21.2K ﹤0.01% 2517
2022
Q2 		$76K Buy
+27,245
New +$109K ﹤0.01% 2338
2022
Q1 		– Sell
-10,527
Closed -$96K – 1605
2021
Q4 		$96K Buy
10,527
+294
+3% +$3K ﹤0.01% 1552
2021
Q3 		$109K Buy
+10,233
New +$125K ﹤0.01% 1721
2018
Q4 		– Sell
-96,000
Closed -$3.04M – 1303
2018
Q3 		$3.04M Sell
96,000
-13,500
-12% -$503K 0.02% 540
2018
Q2 		$4.25M Buy
109,500
+2,100
+2% +$66.9K 0.06% 206
2018
Q1 		$2.96M Sell
107,400
-73,200
-41% -$1.66M 0.04% 286
2017
Q4 		$3.27M Buy
+180,600
New +$2.94M 0.04% 263
2017
Q3 		– Sell
-92,361
Closed -$1.28M – 667
2017
Q2 		$1.28M Buy
92,361
+23,361
+34% +$338K 0.02% 373
2017
Q1 		$1.03M Buy
+69,000
New +$955K 0.02% 366

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Mirae Asset Global Investments's HRTX Position: Q2 2024 in Review

Mirae Asset Global Investments sold out of Heron Therapeutics (HRTX) in Q2 2024, closing a stake of 32,615 shares — an estimated $52.5K sold.

Mirae Asset Global Investments first reported a position in HRTX in Q1 2017 and held it in 13 quarters. The position peaked at $4.25M in Q2 2018. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2024.

  • Mirae Asset Global Investments reported no remaining Heron Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 32,615 Heron Therapeutics shares in Q2 2024, an estimated $52.5K.
  • Mirae Asset Global Investments first reported a position in Heron Therapeutics in Q1 2017 and held it in 13 quarters.
  • Mirae Asset Global Investments's Heron Therapeutics position peaked at $4.25M in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2024.

Based on Mirae Asset Global Investments's 13F filing for Q2 2024, filed 30 Jul 2024.